[{"data":1,"prerenderedAt":166},["ShallowReactive",2],{"drug-rho-d-immune-globulin":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":23,"regimens":38,"contraindications":62,"warnings":72,"renal":73,"monitoring":74,"interactions":75,"review":76,"examples":79,"atc":85,"iran":87,"links":111,"populations":126,"usApproval":161},"rho-d-immune-globulin",1,{"fa":7,"en":8},"ایمونوگلوبولین Rh (آنتی‌D، رگام)","Rho(D) immune globulin (anti-D)","anti-infectives",{"fa":11,"en":12},"ایمونوگلوبولین اختصاصی","Specific immune globulin",[14],{"name":15,"market":16},"RhoGAM","US",[18,19,20,21,22],"rhogam","رگام","آنتی دی","anti-D","روگام",[24],{"id":25,"form":26,"route":27,"label":28,"concentration":29,"markets":33,"refs":34},"syr-300","injection","im","300 mcg (1500 IU) prefilled syringe",{"amount":30,"unit":31,"perUnit":32},300,"mcg","vial",[16],[35],{"source":36,"section":37},"fda-rhogam","3",[39],{"id":40,"disease":41,"label":42,"population":45,"type":49,"unit":31,"dose":50,"refs":51,"durationDays":54,"notes":55},"std","rh-prophylaxis",{"fa":43,"en":44},"مادر Rh منفی — ۳۰۰ mcg عضلانی (هفته ۲۶ تا ۲۸، پس از زایمان، سقط یا عارضه)","Rh-negative mother — 300 mcg IM (26–28 weeks, postpartum, abortion or complication)",{"minAge":46},{"value":47,"unit":48},12,"year","fixed",{"perDose":30,"dosesPerDay":5},[52],{"source":36,"section":53},"2.1",{"min":5,"max":5},[56],{"text":57,"refs":60},{"fa":58,"en":59},"بارداری: هفته ۲۶ تا ۲۸. پس از زایمان (اگر نوزاد Rh مثبت): ظرف ۷۲ ساعت. سقط، حاملگی خارج رحمی، روش تهاجمی یا ترومای بعد از ۱۳ هفته: ظرف ۷۲ ساعت. خونریزی جنینی-مادری بیش از ۱۵ mL گلبول قرمز: ۲۰ mcg به ازای هر mL گلبول قرمز Rh مثبت، گرد به سرنگ کامل بعدی.","Pregnancy: 26–28 weeks. Postpartum (if newborn Rh-positive): within 72 h. Abortion, ectopic, invasive procedure or trauma after 13 weeks: within 72 h. Fetal-maternal haemorrhage >15 mL red cells: 20 mcg per mL of Rh-positive red cells, rounded up to the next whole syringe.",[61],{"source":36,"section":53},[63],{"id":64,"severity":65,"text":66,"refs":69},"ci","block",{"fa":67,"en":68},"افراد Rh مثبت؛ سابقه آنافیلاکسی یا واکنش سیستمیک شدید به ایمونوگلوبولین انسانی.","Rh-positive individuals; history of anaphylaxis or severe systemic reaction to human immune globulin.",[70],{"source":36,"section":71},"4",[],[],[],[],{"status":77,"reviewer":78,"date":78},"unverified",null,[80],{"regimen":40,"formulation":25,"input":81,"expect":84},{"ageYears":82,"weightKg":83},28,70,{"perDose":30},[86],"J06BB01",{"status":88,"forms":89,"refs":106},"registered",[90,94,98,102],{"code":91,"en":92,"fa":93},"02370","ANTI- D IMMUNE GLOBULIN 100MCG\u002F2ML AMP","آمپول ضد–D ایمونوگلوبولین ۱۰۰ میکروگرم \u002F ۲ میلی‌لیتر",{"code":95,"en":96,"fa":97},"01098","ANTI- D IMMUNE GLOBULIN 250 MCG AMP","آمپول ضد–D ایمونوگلوبولین ۲۵۰ میکروگرم",{"code":99,"en":100,"fa":101},"01099","ANTI- D IMMUNE GLOBULIN 300 MCG INJ","فرآورده تزریقی ضد–D ایمونوگلوبولین ۳۰۰ میکروگرم",{"code":103,"en":104,"fa":105},"52345","ANTI-D IMMUNOGLOBULIN INJECTION, SOLUTION INTRAMUSCULAR 300 ug\u002F2mL","فرآورده تزریقی ضد–D ایمونوگلوبولین ۳۰۰ میکروگرم \u002F ۲ میلی‌لیتر",[107],{"source":108,"section":109,"url":110},"darooyab-generic","G-3426\u002FAnti-D-Immunoglobulin-IM","https:\u002F\u002Fwww.darooyab.ir\u002FG-3426\u002FAnti-D-Immunoglobulin-IM",[112,116,120,123],{"kind":113,"url":114,"label":115},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=103777","BLA103777",{"kind":117,"url":118,"label":119},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=d87e4d0b-2442-4135-b3f9-5c4f74845b87","FDA RhoGAM",{"kind":121,"url":122,"label":86},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=J06BB01",{"kind":124,"url":110,"label":125},"darooyab","Anti-D-Immunoglobulin-IM",{"pregnancy":127,"lactation":136,"pediatric":144,"geriatric":153},{"level":128,"text":129,"quote":132,"refs":133},"caution",{"fa":130,"en":131},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","RhoGAM is indicated for administration to Rh-negative women not previously sensitized to the Rho(D) factor, unless the father or baby are conclusively Rh-negative, in case of: Delivery of an Rh-positive baby irrespective of the ABO groups of the mother and baby Antepartum prophylaxis at 26 to 28 weeks gestation …",[134],{"source":36,"section":135},"1.1",{"level":128,"text":137,"quote":140,"refs":141},{"fa":138,"en":139},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary RhoGAM can be used during breastfeeding.",[142],{"source":36,"section":143},"8.2",{"level":145,"text":146,"quote":149,"refs":150},"not-established",{"fa":147,"en":148},"برچسب: ایمنی و اثربخشی در کودکان ثابت نشده است.","Label: safety and effectiveness in children have not been established.","Safety and effectiveness in pediatric patients have not been established.",[151],{"source":36,"section":152},"8.4",{"level":128,"text":154,"quote":157,"refs":158},{"fa":155,"en":156},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","No clinical studies have been performed in geriatric subjects.",[159],{"source":36,"section":160},"8.5",{"kind":162,"refs":163,"id":115},"BLA",[164],{"source":36,"section":165},"SPL approval \u002F marketing category",1792111467044]